NCT06847438 Tailored Electronic Intervention to Improve Therapy in a Diverse Cohort of Patients With Heart Failure
| NCT ID | NCT06847438 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Emory University |
| Condition | Heart Failure |
| Study Type | INTERVENTIONAL |
| Enrollment | 4,000 participants |
| Start Date | 2025-03-24 |
| Primary Completion | 2026-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 4,000 participants in total. It began in 2025-03-24 with a primary completion date of 2026-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Recent medical guidelines for the management of heart failure (HF) have established a combination of specific classes of medications as the best treatment for patients with heart failure with reduced ejection fraction (HFrEF). However, studies have shown that these medications, known together as guideline-directed medical therapy (GDMT), are not being used in clinical practice less often than they could be. Several tools to promote broader use of these treatments (including patient checklists) have shown promise for increasing use of GDMT. However, these tools have not been broadly implemented within large health systems. The goal of this study is to see if using these tools broadly within cardiology clinics will increase the use of GDMT. This study is important because it could help improve the use of GDMT, which may lead to improved patient care and outcomes.
Eligibility Criteria
Inclusion Criteria: * Ejection fraction (EF) less than or equal to 40% by echocardiogram performed in the prior 18 months * Diagnosis of heart failure Exclusion Criteria: * Heart failure (HF) etiology for which GDMT is not indicated: including hypertrophic or restrictive cardiomyopathy (e.g. amyloid cardiomyopathy), constrictive pericarditis, or complex congenital heart disease * End-stage HF requiring continuous inotrope infusion, heart transplant, or left ventricular assist device * Estimated glomerular filtration rate (eGFR) \< 15 mL/min/1.73m\^2 * Any conditions other than HF that are likely to alter the patient's status over 6 months, indicated by active hospice status
Contact & Investigator
Neal W Dickert, MD, PhD
PRINCIPAL INVESTIGATOR
Emory University
Frequently Asked Questions
Who can join the NCT06847438 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Heart Failure. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06847438 currently recruiting?
Yes, NCT06847438 is actively recruiting participants. Contact the research team at njr@emory.edu for enrollment information.
Where is the NCT06847438 trial being conducted?
This trial is being conducted at Atlanta, United States, Atlanta, United States, Atlanta, United States, Johns Creek, United States.
Who is sponsoring the NCT06847438 clinical trial?
NCT06847438 is sponsored by Emory University. The principal investigator is Neal W Dickert, MD, PhD at Emory University. The trial plans to enroll 4,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.